The β3 (beta 3) adrenergic receptor agonist or β3-adrenoceptor agonist, also known as β3-AR agonist, are a class of medicine that bind selectively to β3-adrenergic receptors.
β3-AR agonists for the treatment of obesity and type 2 diabetes have been in developmental stages within many large pharmaceutical companies since the early 1990s without successfully delivering an anti-obesity product to the market. More recently pharmaceutical companies have developed selective β3-AR agonists targeted at urinary inconsistencies and in 2012 Mirabegron (trade name Myrbetriq and Betmiga) was the first β3-AR agonist to be approved in the United States and Europe for the treatment of overactive bladder (OAB) syndrome.[1][2]
- ^ Cite error: The named reference
:0was invoked but never defined (see the help page). - ^ "Press Announcements - FDA approves Myrbetriq for overactive bladder". wayback.archive-it.org. Archived from the original on 2017-01-12. Retrieved 2018-10-03.